With global incidence exceeding 389.000 new cases annually, OSCC remains one of the most common tumors worldwide, and this scenario is projected to get worse, as the incidence is estimated to rise 65% by 2050, as estimated by the [(4) GLOBOCAN]. Prevalence fluctuates significantly depending on the population, with crude rates ranging from 1.1 in African populations to 9.9 in populations from Oceania. Moreover, the burden is distinct between different countries, with a clear association with human development index (HDI) and both incidence and mortality. Regarding incidence,